Study: NCT02466815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Current Clinical Formulation (G-018)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation I (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 Prototype Formulation II (G-025)
Description: JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.